[Effects of glucagon-like peptide-1 on appetite and body weight: preclinical and clinical data].

Abstract

Obesity is associated with an increased risk of developing type 2 diabetes and cardiovascular disease. Pharmacological treatments of diabetes are mostly associated with weight gain, an undesirable event due to the fact that an increase in adiposity, especially visceral, is associated with reduced insulin sensitivity, worse cardiovascular risk profile and decreased adherence to treatment. Analogues of glucagon-like peptide-1 (GLP-1) represent a new therapeutic option for type 2 diabetes, which offer the advantage of combining beneficial effects on metabolic control with a significant reduction in body weight. In this review, we discuss data of preclinical studies and clinical trials that evaluated the effects of liraglutide and exenatide, the two analogues of GLP-1 currently available in Italy, on body weight.

• Authors: Giorgio Sesti
• Journal: Giornale italiano di cardiologia (2006) (G Ital Cardiol (Rome)) Vol. 12 Issue 12 Suppl 2 Pg. 10-6 (Dec 2011) ISSN: 1827-6806 [Print] Italy
• Vernacular Title: Effetti del glucagon-like peptide-1 sull'appetito e sul peso: dati preclinici e studi clinici.
• PMID: 22158422 (Publication Type: Journal Article, Review)

Chemical References

• Hypoglycemic Agents
• Peptides
• Venoms
• Liraglutide
• Glucagon-Like Peptide 1
• Exenatide

Topics

• Appetite (drug effects)
• Body Mass Index
• Body Weight (drug effects)
• Clinical Trials as Topic
• Diabetes Mellitus, Type 2 (drug therapy, metabolism)
• Evidence-Based Medicine
• Exenatide
• Glucagon-Like Peptide 1 (analogs & derivatives, therapeutic use)
• Humans
• Hypoglycemic Agents (therapeutic use)
• Insulin-Secreting Cells (drug effects)
• Liraglutide
• Models, Animal
• Obesity (drug therapy, metabolism)
• Peptides (therapeutic use)
• Treatment Outcome
• Venoms (therapeutic use)